Source:http://linkedlifedata.com/resource/pubmed/id/19582452
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2009-12-24
|
| pubmed:abstractText |
Evidence suggests that the JAK2 V617F mutation is associated with an increased risk of first thrombosis in patients with essential thrombocythemia (ET). Whether this mutation is also a risk factor for recurrent thrombosis is currently unknown. To investigate the impact of the JAK2 V617F mutation on the risk of recurrent thrombosis in patients with ET, we carried out a multicentre retrospective cohort study. We recruited 143 patients with previous arterial (64.4%) or venous major thrombosis (34.8%) or both (0.8%); 98 of them (68.5%) carried the mutation. Thrombosis recurred in 43 of the patients (30%); overall, after adjustment for sex, age, presence of vascular risk factors, and treatment after the first thrombosis, the presence of the JAK2 mutation did not predict recurrence (multivariable hazard ratio, HR, 0.88, 95% CI 0.46-1.68). Indeed, the individuals homozygous for the JAK2 V617F (allele burden >50%) mutation had an increased risk of recurrence in comparison with wild-type patients (HR 6.15, 95% CI 1.51-24.92). In conclusion, a homozygous JAK2 V617F mutation is an independent risk factor for recurrent thrombosis in patients with ET.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1432-0584
|
| pubmed:author |
pubmed-author:BarbuiTizianoT,
pubmed-author:CacciolaEmmaE,
pubmed-author:CacciolaRossella RRR,
pubmed-author:De StefanoValerioV,
pubmed-author:ElliElenaE,
pubmed-author:FinazziGuidoG,
pubmed-author:GIMEMA Chronic Myeloproliferative Neoplasms Working Party,
pubmed-author:GuglielmelliPaolaP,
pubmed-author:GugliottaLuigiL,
pubmed-author:LeoneGiuseppeG,
pubmed-author:MicòCaterinaC,
pubmed-author:PieriLisaL,
pubmed-author:PoglianiEnrico MEM,
pubmed-author:RodeghieroFrancescoF,
pubmed-author:RossiElenaE,
pubmed-author:RuggeriMarcoM,
pubmed-author:SantoroCristinaC,
pubmed-author:ScognamiglioFrancescaF,
pubmed-author:TieghiAlessiaA,
pubmed-author:VannucchiAlessandro MAM,
pubmed-author:VianelliNicolaN,
pubmed-author:ZaTommasoT
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
89
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
141-6
|
| pubmed:meshHeading |
pubmed-meshheading:19582452-Adult,
pubmed-meshheading:19582452-Aged,
pubmed-meshheading:19582452-Aged, 80 and over,
pubmed-meshheading:19582452-Female,
pubmed-meshheading:19582452-Humans,
pubmed-meshheading:19582452-Janus Kinase 2,
pubmed-meshheading:19582452-Male,
pubmed-meshheading:19582452-Middle Aged,
pubmed-meshheading:19582452-Mutation,
pubmed-meshheading:19582452-Risk Factors,
pubmed-meshheading:19582452-Thrombocythemia, Essential,
pubmed-meshheading:19582452-Thrombosis,
pubmed-meshheading:19582452-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
|
| pubmed:affiliation |
Institute of Hematology, Catholic University, Largo Gemelli 8, 00168, Rome, Italy. valerio.destefano@rm.unicatt.it
|
| pubmed:publicationType |
Journal Article
|